Biotech News

UroGen Announces Agreement Resolving Patent Litigation Relating to JELMYTO® (mitomycin) for pyelocalyceal solution

UroGen Pharma (URGN)UroGen Pharma2026-06-25 13:46 ESTFDA / regulatory

Agreement reinforces the value of UroGen’s innovation and reflects the strength of the Company’s intellectual property portfolio Teva will be granted a non-exclusive license to sell its generic version of JELMYTO beginning on September 15, 2030, if approved by the FDA PRINCETON, N.J., June 02, 2026

Open original release

Related news

URGNUroGen Pharma2026-06-25 13:46 EST

UroGen Pharma to Present at the Goldman Sachs 47th Annual Global Healthcare Conference

URGNUroGen Pharma2026-06-25 13:46 EST

UroGen Reports 94.5% Six-Month Duration of Response in Phase 3 UTOPIA Trial, Advancing UGN-103 Toward Potential Approval in Recurrent Low-Grade Intermediate-Risk NMIBC

URGNUroGen Pharma2026-06-25 13:46 EST

ZUSDURI Median Duration of Response Still Not Reached with 64.5% 36-month Duration of Response in the Pivotal ENVISION Trial

URGNUroGen Pharma2026-06-25 13:46 EST

UroGen Pharma to Present at Upcoming Investor Conferences

URGNUroGen Pharma2026-06-25 13:46 EST

UroGen Pharma to Present at the TD Cowen 46th Annual Health Care Conference

URGNUroGen Pharma2026-06-25 13:46 EST

ZUSDURI™ Achieves Durable Complete Responses Across EORTC Risk Groups in Patients with Recurrent LG-IR-NMIBC

URGNUroGen Pharma2026-06-25 13:46 EST

UroGen Announces Refinanced Term Loan Agreement with Pharmakon Advisors

URGNUroGen Pharma2026-06-25 13:46 EST

UroGen Announces ZUSDURI™ Launch is On-Track and Reports Fourth Quarter and Full Year 2025 Financial Results

URGNUroGen Pharma2026-06-25 13:46 EST

UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

URGNUroGen Pharma2026-06-25 13:46 EST

UroGen Applauds BCAN’s New Faces of Bladder Cancer Report Highlighting Recurrence Burden and Fear of Recurrence

View all latest news

UroGen Pharma

UroGen Pharma is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.

Recent company news

URGNUroGen Pharma2026-06-26 08:21 EST

UroGen Announces Agreement Resolving Patent Litigation Relating to JELMYTO® (mitomycin) for pyelocalyceal solution

URGNUroGen Pharma2026-06-26 08:21 EST

UroGen Pharma to Present at the Goldman Sachs 47th Annual Global Healthcare Conference

URGNUroGen Pharma2026-06-26 08:21 EST

UroGen Reports 94.5% Six-Month Duration of Response in Phase 3 UTOPIA Trial, Advancing UGN-103 Toward Potential Approval in Recurrent Low-Grade Intermediate-Risk NMIBC

URGNUroGen Pharma2026-06-26 08:21 EST

ZUSDURI Median Duration of Response Still Not Reached with 64.5% 36-month Duration of Response in the Pivotal ENVISION Trial

URGNUroGen Pharma2026-06-26 08:21 EST

UroGen Pharma to Present at Upcoming Investor Conferences

Stock data

Close: —
Market cap: —
Exchange: NASDAQ
Sector: Biotechnology
Location: United States